Numerous clinical trials involving the use of
melanoma tumor vaccines have been conducted or are underway.
Not exact matches
The
melanoma vaccine slowed cancer growth, and the cervical cancer
vaccine shrank
tumors.
The
vaccine was administered to six patients with
melanoma whose
tumors had been removed by surgery and who were considered at high risk for recurrence.
A personal cancer treatment
vaccine that targets distinctive «neoantigens» on
tumor cells has been shown to stimulate a potent, safe, and highly specific immune anti-
tumor response in
melanoma patients, report scientists from Dana - Farber Cancer Institute and the Broad Institute of MIT and Harvard.
As demonstrated by the breadth of clinical trial involvement shown above, CCIR members are testing the utility of immune checkpoint blockade in lymphoma (shown by Dr. Allison to be effective against
melanoma), genetic engineering in cell therapy (e.g., CD19, CXCR2, TGF - β DNR), and TLR agonists or IL - 2 in
vaccine formulations as well as some novel combination therapies, such as the infusion of
tumor - reactive lymphocytes from HLA - matched donors who were vaccinated with a lymphoma idiotype.
At first, analyzing a patient's surgically removed
tumor and developing a
vaccine against 10 specific targets on the
tumor took nine months, says Greg Lizée, Ph.D., associate professor of
Melanoma Medical Oncology, whose research focuses on the immune system.